Asian Pharmaceutical Firm to Evaluate IntelliGel®
February 26, 2018 1:30 pmRedwood Pharma has signed a Materials Transfer Agreement where an Asian pharmaceutical firm will obtain IntelliGel® for the purposes of... View Article
Redwood Pharma has signed a Materials Transfer Agreement where an Asian pharmaceutical firm will obtain IntelliGel® for the purposes of... View Article
Redwood Pharma has met with the Swedish Medical Products Agency in an advisory discussion. The meeting gave the company the... View Article
The United States Patent and Trade Mark Office (USPTO) has communicated its intention to grant a new US patent in... View Article
Redwood Pharma will be attending BIO-Europe 2018 in Amsterdam, Mar. 11 – 14 to meet and continue discussions with potential... View Article
CEO Martin Vidaeus explains about development through toxicology and safety studies. About RP101 RP101 is the company’s main development program... View Article
Following successfully completed toxicology and safety studies, Redwood Pharma has now started production of the drug RP101 for use in... View Article
Redwood Pharma AB (publ) announces that the RP101 toxicology studies are now successfully completed. The Company can thereby continue the... View Article
Redwood Pharma will be attending Bio-Europe 2017 in Berlin, Nov. 6 – 8 to meet and continue discussions with potential... View Article
Redwood Pharma AB (publ) has contracted the Swiss contract research organization (CRO) CROss Alliance® for the management of a clinical... View Article
Medicines that are used in clinical trials are stringently regulated. Regulated production begins now of the active pharmaceutical ingredient in... View Article